within Pharmacolibrary.Drugs.ATC.J;

model J01DF01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0018333333333333333,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.008,
    k12             = 6,
    k21             = 6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DF01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Aztreonam is a monobactam antibiotic used primarily to treat infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. It is administered mainly by intravenous or intramuscular injection and is approved for use in various countries today, particularly for patients with beta-lactam allergies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult healthy volunteers after single dose intravenous administration.</p><h4>References</h4><ol><li><p>Mattie, H (1988). Clinical pharmacokinetics of aztreonam. <i>Clinical pharmacokinetics</i> 14(3) 148–155. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198814030-00003&quot;>10.2165/00003088-198814030-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3286083/&quot;>https://pubmed.ncbi.nlm.nih.gov/3286083</a></p></li><li><p>Burgess, DS, et al., &amp; Hardin, TC (1999). Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. <i>Clinical therapeutics</i> 21(11) 1882–1889. DOI:<a href=&quot;https://doi.org/10.1016/S0149-2918(00)86736-3&quot;>10.1016/S0149-2918(00)86736-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10890260/&quot;>https://pubmed.ncbi.nlm.nih.gov/10890260</a></p></li><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=&quot;https://doi.org/10.1007/s40272-013-0017-5&quot;>10.1007/s40272-013-0017-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23529866/&quot;>https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DF01;
